Sensitivity and Specificity of Cytokines in the Diagnosis of Lymphoma-associated HLH

Lymphoma-associated hemophagocytic lympohistiocytosis is a refractory immune disorder with high mortality. Early identification and diagnosis of lymphoma-associated HLH has become the key to improve the prognosis of lymphoma-associated HLH. Therefore, we conduct a multicenter, prospective, observational clinical study to explore the sensitivity and specificity of cytokines for the early diagnosis of lymphoma-associated HLH.

Inclusion Criteria:Age 40-75, gender is not limited.Patients with histopathologically confirmed lymphoma who meet HLH-04 diagnostic criteria, and did not receive systemic chemotherapy before enrollment.Patients with histopathologically confirmed lymphoma who did not receive systemic chemotherapy before enrollment.Informed consent obtained.Exclusion Criteria:Patients with severe active infections (viral, bacterial, fungal, or parasitic).Patients with active autoimmune disease or a history of organ transplantation who are receiving immunosuppressive therapy.Patients with other type of malignant tumors within 5 years, except for cured solid tumors.Patients planned to receive immunotherapy.Pregnant and breastfeeding females.History of human immunodeficiency virus (HIV) infection.Acute or chronic active hepatitis B or hepatitis C.Patients assessed as ineligible for the study by the investigator.